Document:

Document

Exhibit 10.2
EMPLOYMENT   AGREEMENT

THIS AGREEMENT is entered into as of May 1, 2017 ("Commencement Date"), by and between Ronald Prague (the "Executive") and Synchronoss Technologies, Inc., a Delaware corporation (the "Company"). Executive and the Company agree that the Employment Agreement dated as of January 1, 2015 between the Company and the Executive shall be terminated as of April 30, 2017.

Except as otherwise provided herein, defined terms are set forth in Section 10 below.
1.Duties and Scope of Employment.

(a)Position. For the term of his employment under this Agreement (the "Employment"), the Company agrees to employ Executive in the position of Executive Vice President, General Counsel, Chief Legal Officer and Secretary. Executive shall report to the Company's Chief Executive Officer or his or her designee. Executive's principal workplace shall be in Bridgewater, New Jersey.

(b)Obligations to the Company. During his Employment, Executive (i) shall devote substantially all of his full business efforts and time to the Company, (ii) shall not engage in any other employment, consulting or other business activity that would create a conflict of interest with the Company, (iii) shall not assist any person or entity in competing with the Company or in preparing to compete with the Company, (iv) shall comply with the Company' s policies and rules, as they may be in effect from time to time and (v) shall comply with the Proprietary Information and Inventions Agreement. This provision shall not restrict Executive's ability to sit on non-profit boards and, subject to Board approval, at least one corporate board.

(c)No Conflicting Obligations. Executive represents and warrants to the Company that he is under no obligations or commitments, whether contractual or otherwise, that are inconsistent with his obligations under this Agreement. Executive represents and warrants that he will not use or disclose, in connection with his Employment, any trade secrets or other proprietary information or intellectual property in which Executive or any other person has any right, title or interest and that his Employment will not infringe or violate the rights of any other person.  Executive represents and
warrants to the Company that he has returned all property and confidential information belonging to any prior employer.

(d)lndemnification/D&O Insurance. To the maximum extent permitted by applicable law and the Company' s by-laws, the Company shall indemnify Executive for all acts and omissions by him and any action on his part while acting in such capacity, and for losses that arise from serving at the request of the Company or a subsidiary thereof as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise. Executive shall be covered by directors' and officers' liability insurance on a basis no less favorable than provided to directors and officers of the Company, including "tail" coverage.

(e)Commencement Date. Executive has previously commenced full-time Employment. This

Agreement shall govern the terms of Executive' s Employment effective as the Commencement Date through the Term (as defined in Section 5(a) below).

2. Compensation

(a)Salary. The Company shall pay Executive as compensation for his services a base salary at a gross annual rate of not less than $330,000. Such salary shall be payable in accordance with the Company's standard payroll procedures. (The annual compensation specified in this Subsection (a), together with any increases in such compensation that the Company may grant from time to time, is referred to in this Agreement as " Base Salary." )

(b)Incentive Bonuses. Executive shall be eligible for an annual incentive bonus with a target amount equal to 60% of his Base Salary (the "Target Bonus"). Executive's bonus (if any) shall be awarded based on criteria established by the Company's Board of Directors (the "Board") or its Compensation Committee. Executive shall not be entitled to an incentive bonus for a fiscal year if he is not employed by the Company on the last day of the fiscal year for which such bonus is payable or is provided notice of termination under Section 5(b) prior to such time. Any bonus for a fiscal year shall be paid within 2Yi months after the close of that fiscal year. The determinations of the Board or its Compensation Committee with respect to such bonus shall be final and binding.

3. Paid Time Off and Employee Benefits. During his Employment, Executive shall be eligible for paid time off in accordance with the Company's paid time off policy, as it may be amended from time to time, with a minimum of 20 paid time off days per year (accruing for each year on the first day of such year), plus three floating holidays, and any United States Company wide holidays; provided, however, Executive shall not be entitled to carry over any paid time off days from year to year. During his Employment, Executive shall be eligible to participate in the employee benefit plans maintained by the Company, subject in each case to the terms and conditions of the plan in question.

4. Business Expenses. During his Employment, Executive shall be authorized to incur necessary and reasonable travel, entertainment and other business expenses in connection with his duties hereunder. Notwithstanding anything to the contrary herein, except to the extent any expense or reimbursement provided pursuant to this Agreement does not constitute a "deferral of compensation" within the meaning of Section 409A of the Code, (a) the amount of expenses eligible for reimbursement provided to Executive during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to Executive in any other calendar year, (b) the reimbursements for expenses for which Executive is entitled to be reimbursed shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred and (c) the right to payment or reimbursement hereunder may not be liquidated or exchanged for any other benefit.

5. Term of Employment.

(a)Employment Term. The Company hereby employs Executive to render services to the Company in the position and with the duties and responsibilities described in Section 1 for the period commencing on the Commencement Date and ending upon the earlier of (i) the date of Executive's resignation from the Company and (ii) the date Executive' s Employment is terminated in accordance with Section 5(b) (the "Term").

(b) Termination of Employment. The Company may terminate Executive's Employment at any time and for any reason (or no reason), and with or without Cause, by giving Executive 30 days' advance notice in writing. Executive may terminate his Employment by giving the Company 30 days' advance notice in writing. The Company shall have the right at any time during such 30- day period, to relieve Executive of his offices, duties and responsibilities and place him on a paid leave-of-absence status, provided that during such notice period, Executive shall remain a full time employee of the Company and shall continue to receive his then current salary compensation and other benefits as provided in this Agreement. Executive's Employment shall terminate automatically in the event of his death. The termination of Executive's Employment shall not limit or otherwise affect his obligations under Section 7.

(c) Rights Upon Termination. Upon Executive 's termination of Employment for any reason, Executive shall be entitled to the compensation, benefits and reimbursements described in Sections 1, 2, 3, and 4 for the period preceding the effective date of such termination or otherwise accrued before such termination. Upon the termination of Executive' s Employment under certain circumstances, Executive may be entitled to additional severance pay benefits described in Section The payments under this Agreement shall fully discharge all responsibilities of the Company to Executive. This Agreement shall terminate when all obligations of the parties hereunder have been satisfied.

(d) Rights Upon Death. If Executive's Employment ends due to death, (A) Executive's estate shall be entitled to receive an amount equal to his target bonus for the fiscal year in which his death occurred (or, if greater, the bonus amount determined based on the applicable factors and actual performance for such fiscal year), prorated based on the number of days he was employed by the Company during that fiscal year and (B) all stock options, shares of restricted stock (other than performance-related restricted stock), and other time-based equity awards granted by the Company and held by Executive at the time of his death shall be fully vested. All amounts under this Section 5(d) shall be paid no later than the date all regular employees are paid their bonuses.

(e) Rights Upon Permanent Disability. If Executive's Employment ends due to Permanent Disability and a Separation occurs, (I) Executive shall be entitled to receive (i) an amount equal to his Target Bonus for the fiscal year in which his Employment ended (or, if reasonably ascertainable and greater, the bonus amount determined based on the applicable factors and actual performance for such fiscal year), prorated based on the number of days he was employed by the Company during that fiscal year, and (ii) a lump sum amount equal to the product of (A) 24 and (B) the monthly amount the Company was paying on behalf of Executive and his eligible dependents with respect to the Company' s health insurance plans in which Executive and his eligible dependents were participants as of the date of Separation, and (II) all stock options, shares of restricted stock (other than performance-related restricted stock) and other time-based equity awards granted by the Company and held by Executive shall be fully vested as of the date of Executive's Separation. The amounts payable under this Section 5(e) shall be paid no later 60 days after Executive's Separation.

6.Termination Benefits.

(a)Preconditions. Any other provision of this Agreement notwithstanding, Subsections (b) and (c) below shall not apply unless Executive:

(i)Has executed (or, with respect to Section 5(d), the executor or his estate has executed)  a

general release of all claims Executive (or his executor or estate) may have against the Company or persons affiliated with the Company (substantially in the form attached hereto as Exhibit A) (the "Release");

i.Complies with Executive' s obligations under Section 7 of this Agreement;

ii.Has returned all property of the Company in Executive' s possession; and

iii.If requested by the Board, has resigned as a member of the Board and as a member of the boards of directors of all subsidiaries of the Company, to the extent applicable.

Executive must execute and return the Release within the period of time set forth in the Release (the "Release Deadline"). The Release Deadline will in no event be later than 50 days after Executive's Separation. If Executive fails to return the Release on or before the Release Deadline or if Executive revokes the Release, then Executive will not be entitled to the benefits described in this Section 6.

(b) Severance Pay in the Absence of a Change in Control. If, during the term of this Agreement and not at a time described in subsection (c) below, Executive resigns his Employment for Good Reason and a Separation occurs or the Company terminates Executive's Employment with the Company for a reason other than death, Cause or Permanent Disability and a Separation occurs, then the Company shall pay Executive a lump sum severance payment equal to (i) one and one-half times (A) his Base Salary in effect at the time of the termination of Employment plus, (B) his average annual bonus based on the actual amounts received in the immediately preceding two years and (ii) the product of (A) 24 and (B) the monthly amount the Company was paying on behalf of Executive and his eligible dependents with respect to the Company's health insurance plans in which Executive and his eligible dependents were participants as of the date of Separation. In the event that Executive Employment is terminated for a reason other than death, Cause or Permanent Disability or Executive resigns his Employment for Good Reason under this Subsection within two years after commencement of employment with the Company, then in lieu of using the average bonus received in the immediately preceding two years for the above calculation, such calculation shall use his Target Bonus in the year of termination if such termination under this Subsection (b) occurs in the first year of employment with the Company and the actual bonus Executive received during the first year of employment with the Company if such termination under this Subsection (b) occurs in the second year of employment with the Company. However, the amount of the severance payment under this Subsection (b) shall be reduced by the amount of any severance pay or pay in lieu of notice that Executive receives from the Company under a federal or state statute (including, without limitation, the Worker Adjustment and Retraining Notification Act).

(c)Severance Pay in Connection with a Change in Control. If , during the term of this Agreement and within (i) 120 days prior to or (ii) 24 months following a Change in Control, Executive is subject to an Involuntary Termination, then (i) the Company shall pay Executive a lump sum severance payment equal to (x) two times his Base Salary in effect at the time of the termination of Employment plus two times Executive's average bonus received in the immediately preceding two years and (y) a lump sum amount equal to the product of (A) 24 and (B) the monthly amount the Company was paying on behalf of Executive and his eligible dependents with respect to the Company' s health insurance plans in which Executive and his eligible dependents were participants as of the date of Separation, and (ii) all stock options, shares of restricted stock (other

than performance-related restricted stock that is tied to performance after the Change in Control), and other time-based equity awards granted by the Company and held by Executive shall be fully vested as of the date of the Involuntary Termination. In the event that Executive is subject to an Involuntary Termination under this Subsection (c) within two years after commencement of employment with the Company, then in lieu of using the average bonus received in the immediately preceding two years for the above calculation, such calculation shall use his Target Bonus in the year of the Involuntary Termination if such termination under this Subsection (c) occurs in the first year of employment with the Company and the actual bonus Executive received during the first year of employment with the Company if such termination under this Subsection 
(c)occurs in the second year of employment with the Company. However, the amount of the severance payment under this Subsection (c) shall be reduced by the amount of any severance pay or pay in lieu of notice that Executive receives from the Company under a federal or state statute (including, without limitation, the Worker Adjustment and Retraining Notification Act).

(d)Commencement of Severance Payments. Payment of the severance pay provided for under this Agreement will be made no later than the first regularly scheduled payroll date that occurs no later than 50 days after Executive' s Separation, but only if Executive has complied with the release and other preconditions set forth in Subsection (a) (to the extent applicable). However, except as provided in the next following sentence, if the 50-day period described in Section 5(a) spans two calendar years, then the payment will be made on the first payroll date in the second calendar year following expiration of the applicable revocation period. In the event that Executive experiences an Involuntary Termination immediately at or after a Change in Control, the Company shall work with the surviving company to ensure that any payments due to Executive under subsection (c) above be paid upon the closing of the Change in Control. In addition, if at any time the parties agree that a Good Reason arises after the Change in Control and severance is due to Executive under subsection (c), the Company shall work with the surviving company to insure that any such payments due to Executive are paid promptly after such Good Reason arises.

(e)Section 409A. This Agreement shall be construed consistently with the intent that all payments hereunder shall be exempt from the requirements of Section 409A of the Code by reason of the "short-term" deferral exemption or a different exemption. Each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments. If the Company determines that Executive is a "specified employee" under Section 409A(a)(2)(B)(i) of the Code at the time of his Separation, then (i) payment of any " nonqualified deferred compensation" (within the meaning of Section 409A) that is payable to Executive upon Separation shall be delayed until the first business day following (A) expiration of the six-month period measured from Executive's Separation, or (B) the date of Executive's death, and (ii) the installments that otherwise would have been paid prior to such date will be paid in a lump sum when such payments commence.

7. Protective Covenants.

(a)Non- Competition. As one of the Company' s executive and management personnel and officer, Executive has acquired extensive and valuable knowledge and confidential information concerning the business of the Company, including certain trade secrets the Company wishes to protect. Executive further acknowledges that during his employment he will have access to and knowledge of Proprietary Information. To protect the Company's Proprietary Information, and in consideration of this Agreement, Executive agrees that during his employment with the Company

and for a period of twelve (12) months after the termination of Executive' s employment with the Company for any reason, whether under this Agreement or otherwise (the " Restricted Period"), he will not without the Company' s approval (which shall not be unreasonably withheld), directly or indirectly engage in (whether as an employee, consultant, proprietor, partner, director or otherwise), have any ownership interest in, or participate in the financing, operation, management or control of, any person, firm, corporation or business that engages in a Restricted Business in a Restricted Territory. It is agreed that ownership of (i) no more than one percent (1%) of the outstanding voting stock of a publicly traded corporation or (ii) any stock he presently owns shall not constitute a violation of this Section.

(b) Non-Solicitation and Non-Servicing. During his employment with the Company and continuing for a period of eighteen (18) months after termination of Executive' s employment with the Company for any reason, whether under this Agreement or otherwise, Executive shall not directly or indirectly, personally or through others,

i.attempt in any manner to solicit, persuade or induce any Client of the Company to terminate, reduce or refrain from renewing or extending its contractual or other relationship with the Company in regard to the purchase or licensing of products or services manufactured, marketed, licensed or sold by the Company, or to become a Client of or enter into any contractual or other relationship with Executive or any other individual, person or entity in regard to the purchase or license of products or services similar or identical to those manufactured, marketed or sold by the Company; or

ii.attempt in any manner to solicit, persuade or induce any individual, person or entity which is, or at any time during Executive' s employment with the Company was, a supplier of any product or service to the Company or vendor of the Company (whether as a distributor , agent, employee or otherwise) to terminate, reduce or refrain from renewing or extending his, her or its contractual or other relationship with the Company; provided, however, this subparagraph (ii) shall not apply with respect to (I) during the first six (6) months after Executive' s Separation, up to two service providers of the Company who report in to Executive' s organization, were recruited by Executive and had worked with Executive in prior employment, plus Executive' s administrative assistant, and (II) during the next six (6) month period thereafter, up to two service providers of the Company who report in to Executive' s organization, were recruited by Executive and had worked with Executive in prior employment; or

iii.render to or for any Client any services of the type rendered by the Company; or

iv.subject to the exceptions in subparagraph (ii) above , employ as an employee or retain as a consultant any person who is then, or at any time during the preceding twelve months was, an employee of or consultant to the Company (unless the Company had terminated the employment or engagement of such employee or exclusive consultant prior to the time of the alleged prohibited conduct), or persuade, induce or attempt to persuade any employee of or consultant to the Company to leave the employ of the Company or to breach any service arrangement with the Company.

(c)Non-Disclosure. Executive has entered into a Proprietary Information and Inventions Agreement with the Company, which is incorporated herein by reference.

(d) Reasonable. Executive agrees and acknowledges that the time limitation on the restrictions in this Section 7, combined with the geographic scope, is reasonable. Executive also acknowledges and agrees that this provision is reasonably necessary for the protection of Proprietary Information, that through his Employment he shall receive adequate consideration for any loss of opportunity associated with the provisions herein, and that these provisions provide a reasonable way of protecting the Company' s business value which will be imparted to him. If any restriction set forth in this Section 7 is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.

8. Successors.

(a)Company's Successors. This Agreement shall be binding upon any successor (whether direct or indirect and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company's business and/or assets. For all purposes under this Agreement, the term "Company" shall include any successor to the Company' s business and/or assets which becomes bound by this Agreement.

(b)Employee's Successors. This Agreement and all rights of Executive hereunder shall inure to the benefit of, and be enforceable by, Executive's personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.

9. Taxes.

(a)Withholding Taxes. All payments made under this Agreement shall be subject to reduction to reflect applicable withholding and payroll taxes or other deductions required to be withheld by law.

(b)Tax Advice. Executive is encouraged to obtain his own tax advice regarding his compensation from the Company. Executive agrees that the Company does not have a duty to design its compensation policies in a manner that minimizes Executive's tax liabilities, and Executive shall not make any claim against the Company or the Board related to tax liabilities arising from Executive's compensation.

(c)Parachute Taxes. Notwithstanding anything in this Agreement to the contrary, if it shall be determined that any payment or distribution by the Company to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise ("Total Payments") to be made to Executive would otherwise exceed the amount (the "Safe Harbor Amount") that could be received by Executive without the imposition of an excise tax under Section 4999 of Code, then the Total Payments shall be reduced to the Safe Harbor Amount if (and only if) the Safe Harbor Amount (net of applicable taxes) is greater than the net amount payable to Executive after taking into account any excise tax imposed under section 4999 of the Code on the Total Payments. All determinations to be made under this subparagraph (c) shall be made by a public accounting firm selected by the Company before the date of the Change in Control (the "Accounting Firm"). In determining whether such Benefit Limit is exceeded, the Accounting Firm shall make a reasonable determination of the value to be assigned to the restrictive covenants in effect for Executive pursuant to Section 7 of this Agreement, and the amount of his potential parachute payment under Section 2800 of the Code shall be reduced   by

the value of those restrictive covenants and all other permissible adjustments to the extent consistent with Section 280G of the Code and the regulations thereunder. To the extent a reduction to the Total Payments is required to be made in accordance with this subparagraph (c), such reduction and/or cancellation of acceleration of equity awards shall occur in the order that provides the maximum economic benefit to Executive. In the event that acceleration of equity awards is to be reduced, such acceleration of vesting also shall be canceled in the order that provides the maximum economic benefit to Executive. Notwithstanding the foregoing, any reduction shall be made in a manner consistent with the requirements of section 409A of the Code and where two economically equivalent amounts are subject to reduction but payable at different times, such amounts shall be reduced on a pro rata basis but not below zero. All of the fees and expenses of the Accounting Firm in performing the determinations referred to in this subparagraph (c) shall be borne solely by the Company.

10. Definitions.

(a)Cause.  For all purposes under this Agreement, "Cause" shall mean:

(i)An intentional and unauthorized use or disclosure by Executive of the Company's confidential information or trade secrets, which use or disclosure causes material harm to the Company;

(ii)A material breach by Executive of any material agreement between Executive and the Company;

(iii)A material failure by Executive to comply with the Company' s written policies or rules;

(iv)Executive's conviction of, indictment for, or plea of "guilty" or "no contest" to, a felony under the laws of the United States or any State thereof;

(v)Executive's gross negligence or willful misconduct which causes material harm to the Company;

(vi)A continued failure by Executive to perform reasonably assigned duties after receiving written notification of such failure from the Board (other than by reason of Executive' s physical or mental illness, incapacity or disability); or

(vii)A failure by Executive to cooperate in good faith with a governmental or internal investigation of the Company or its directors, officers or employees, if the Company has requested in writing Executive' s cooperation, and Executive has not cooperated in good faith within 5 business days.

With respect to subparagraphs (ii), (iii) or (vi), the Company shall not have the right to terminate Executive for Cause if Executive cures the breach or failure within 30 days of the Company' s written notice to Executive of such breach or failure.

(b)Change in Control. For all purposes under this Agreement, " Change in Control" shall mean the occurrence of:

(i)The acquisition, by a person or persons acting as a group, of the Company's stock that, together with other stock held by such person or group, constitutes more than 50% of the total fair market value or total voting power of the Company;

(ii)The acquisition, during a 12-month period ending on the date of the most recent acquisition, by a person or persons acting as a group, of 30% or more of the total voting power of the Company;

(iii)The replacement of a majority of the members of the Board, during any 12-month period, by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of such appointment or election; or

(iv)The acquisition, during a 12-month period ending on the date of the most recent acquisition, by a person or persons acting as a group, of the Company's assets having a total gross fair market value (determined without regard to any liabilities associated with such assets) of 80% or more of the total gross fair market value of all of the assets of the Company (determined without regard to any liabilities associated with such assets) immediately prior to such acquisition or acquisitions.

Notwithstanding the foregoing, a Change in Control shall not be deemed to occur unless such transaction also qualifies as an event under Treas. Reg. §1.409A-3(i)(5)(v) (change in the ownership of a corporation), Treas. Reg. §1.409A-3(i)(5)(vi) (change in the effective control of a corporation), or Treas. Reg. §1.409A-3(i)(5)(vii) (change in the ownership of a substantial portion of a corporation's assets).

(c)Client. For all purposes under this Agreement, " Client" shall mean (i) anyone who is a client of the Company as of, or at any time during the one-year period immediately preceding, the termination of Executive' s employment, but only if Executive had a direct relationship with, supervisory responsibility for or otherwise were involved with such client during Executive's employment with the Company and (ii) any prospective client to whom the Company made a new business presentation (or similar offering of services) at any time during the one-year period immediately preceding, or six-month period immediately following, Executive' s employment termination (but only if initial discussions between the Company and such prospective client relating to the rendering of services occurred prior to the termination date, and only if Executive participated in or supervised such presentation and/or its preparation or the discussions leading up to it).

a.Code. For all purposes under this Agreement, " Code" shall mean the Internal Revenue Code of 1986, as amended.

b.Company. For all purposes under this Agreement, "Company" shall include Synchronoss Technologies, Inc. and all of its subsidiaries and affiliates.

(t)       Good Reason.  For all purposes under this Agreement, " Good Reason" shall mean:

(i)material diminution in Executive' s authorities, duties or responsibilities;

(ii)a reduction in Executive' s base salary by more than 5% unless pursuant to a Company- wide salary reduction affecting all of the Company' s Section 16 officers proportionately;

i.relocation of Executive's principal workplace that results in an increase to Executive's commute by more than 50 miles;

ii.a material reduction in the kind or level of incentive compensation or employee benefits to which Executive is entitled immediately prior to such reduction with the result that Executive' s overall compensation and benefits package is significantly reduced, unless such reduction occurs solely as a result of a reduction in the kind or level of employee benefits of employees that applies for all employees of the Company or

iii.a material breach by the Company of this Agreement.

A condition shall not be considered "Good Reason" unless Executive gives the Company written notice of such condition within 90 days after Executive has knowledge of such condition and the Company fails to remedy such condition (or in the case of (v), remedy such breach) within 30 days after receiving Executive's written notice. In addition, Executive' s resignation must occur no later than 12 months after Executive has knowledge of such condition.

(g)Involuntary Termination. For all purposes under this Agreement, " Involuntary Termination" shall mean either (i) the Company terminates Executive's Employment with the Company for a reason other than death, Cause or Permanent Disability and a Separation occurs, or (ii) Executive resigns his Employment for Good Reason and a Separation occurs.

(h)Permanent Disability. For all purposes under this Agreement, " Permanent Disability" shall mean, in the reasonable determination by the Compensation Committee, Executive' s inability to perform the essential functions of Executive's position, with or without reasonable accommodation, for a period of at least 180 consecutive days because of a physical or mental impairment.

(i)Proprietary Information. For all purposes under this Agreement, " Proprietary Information" shall mean any and all confidential and/or proprietary knowledge, data or information of the Company. By way of illustration but not limitation, Proprietary Information includes (i) trade secrets, inventions , mask works, ideas, processes, formulas, source and object codes, data, programs, other works of authorship, know-how, improvements, discoveries, developments, designs and techniques; and (ii) information regarding plans for research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers; and (iii) information regarding the skills and compensation of other employees of the Company.

(j) Restricted Business. For all purposes under this Agreement, "Restricted Business" shall  mean the design, development, marketing or sales of software, or any other process, system, product, or service marketed, sold or under development by the Company (and expected to reach market before the end of the Restricted Period) at the time Executive' s employment with the Company ends, whether during or after the Term.

(k)Restricted Territory. For all purposes under this Agreement, " Restricted Territory" shall mean any state, county, or locality in the United States or around the world in which the Company conducts business.

(i)Separation.  For all purposes under this Employment Agreement, "Separation" means a

"separation from service," as defined in the regulations under Section 409A of the Code.

(m)   Solicit.  For all purposes under this Agreement, "solicit" shall mean (i) active solicitation of any Client or Company employee (but not general marketing of a product, service or open position not targeted at such employee); (ii) the provision of information regarding any Client or Company employee to any third party where such information could be useful to such third party in attempting to obtain business from such Client or attempting to hire any such Company employee; (iii) participation in any meetings, discussions, or other communications with any third party regarding any Client or Company employee where the purpose or effect of such meeting, discussion or communication is to obtain business from such Client or employ such Company employee; and (iv) any other passive use of information about any Client or Company employee which has the purpose or effect of assisting a third party or causing harm to the business of the Company.

11. Miscellaneous Provisions.

(a)Notice. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given when personally delivered, when delivered by FedEx with delivery charges prepaid, or when mailed by U.S. registered or certified mail, return receipt requested and postage prepaid. In the case of Executive, mailed notices shall be addressed to him at the home address that he most recently communicated to the Company in writing. In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of its Secretary.

(b)Modifications and Waivers. No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive). No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.

(c)Whole Agreement. This Agreement and the Proprietary Information and Inventions Agreement supersede and replace any prior agreements, representations or understandings (whether oral or written and whether express or implied) between Executive and the Company and constitute the complete agreement between Executive and the Company regarding the subject matter set forth herein; provided that nothing in this Agreement shall supersede an express promise made by the Company in Executive's offer letter.

(d)Choice of Law and Severability. This Agreement shall be interpreted in accordance with the laws of the State of New Jersey (except their provisions governing the choice of law). If any provision of this Agreement becomes or is deemed invalid, illegal or unenforceable in any applicable jurisdiction by reason of the scope, extent or duration of its coverage, then such provision shall be deemed amended to the minimum extent necessary to conform to applicable law so as to be valid and enforceable or, if such provision cannot be so amended without materially altering the intention of the parties, then such provision shall be stricken and the remainder of this Agreement shall continue in full force and effect. If any provision of this Agreement is rendered illegal by any present or future statute, law, ordinance or regulation (collectively the "Law"), then such provision shall be curtailed or limited only to the minimum extent necessary to bring   such

provision into compliance with the Law. All the other terms and provisions of this Agreement shall continue in full force and effect without impairment or limitation.

(e) No Assignment. This Agreement and all rights and obligations of Executive hereunder are personal to Executive and may not be transferred or assigned by Executive at any time. The Company may assign its rights under this Agreement to any entity that assumes the Company's obligations hereunder in connection with any sale or transfer of all or a substantial portion of the Company's assets to such entity.

(f) Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

(g) Survival. The rights and obligations of the parties under the provisions of this Agreement (including without limitation Section 7) shall survive, and remaining binding and enforceable, notwithstanding the termination of this Agreement, the termination of Executive's Employment hereunder or otherwise, to the extent necessary to preserve the intended benefits of such provision.

IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the day and year first above written.

						
		/s/ Ronald Prague

		Ronald Prague
		
		SYNCHRONOSS TECHNOLOGIES, INC.
		
		/s/ Stephen G. Waldis
		Stephen G. Waldis
		Chief Executive OfficerDocument

Exhibit 10.1
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type of information that Adamas Pharmaceuticals, Inc. treats as private or confidential.

Execution Version

Adamas-Zydus Binding Term Sheet
						
	Parties	Adamas Pharma, LLC (“Adamas”) and Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA) Inc. (collectively, “Zydus”)

	Overview	On April 30, 2020, Zydus Worldwide DMCC submitted ANDA No. 214897 for amantadine extended release capsules 68.5 mg and 137 mg to the United States Food and Drug Administration (“FDA”) that references Adamas’s NDA No. 208944 and contains  certifications pursuant to 21 U.S.C. 355(j)(2)(A)(vii)(IV) (“Paragraph IV Certification”) with respect to U.S. Patent Nos. 8,389,578, 8,741,343, 8,796,337, 8,889,740, 8,895,614, 8,895,615, 8,895,616, 8,895,617, 8,895,618, 9,867,791, 9,867,792, 9,867,793, 9,877,933, and 10,154,971 (“Zydus’s Paragraph IV Certifications”).  Since that time, Adamas was issued U.S. Patent No. 10,646,456, which is now listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations.  Adamas and Zydus have had discussions to resolve Zydus’s Paragraph IV Certifications, including the negotiation of rights and obligations in connection therewith and certain commercial terms, and each Party has determined that it is in its best interests to execute and be bound by this term sheet in connection therewith (this “Term Sheet”).  Adamas and Zydus is each referred to as a “Party” and, collectively, as the “Parties.”  This Term Sheet shall be considered to be confidential information of the Parties.  
Accordingly, the Parties are executing this Term Sheet as of the date set forth on the signature page hereto (the “Execution Date”) intending to be legally bound by the terms set forth herein and to create legally enforceable obligations and rights as set forth herein.

	Dismissal of Litigation	Adamas and Zydus agree to dismiss without prejudice the case Adamas Pharma, LLC v.Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA) Inc., C.A. No. 20-10463 (BRM)(TJB) in the U.S. District Court for the District of New Jersey (the “Pending Litigation”). The Parties agree to the entry of the Stipulation and Order of Dismissal (see Exhibit A), with each Party bearing its own costs and attorneys’ fees.  Within three (3) business days following the Execution Date, the Parties shall cause the Stipulation and Order of Dismissal to be filed with the United States District Court for the District of New Jersey (the “District Court”) and shall take all other reasonable and necessary actions to obtain the settlement and dismissal of the Pending Litigation.  If for any reason the District Court raises an objection to the Stipulation and Order of Dismissal as drafted or requires that the Parties modify the Stipulation and Order of Dismissal before it will enter it as an order of the District Court, the Parties agree to confer promptly and in good faith in order to take action consistent with this Term Sheet to secure entry of the Stipulation and Order of Dismissal as drafted, or to agree upon modifications to the Stipulation and Order of Dismissal, or to take such other action consistent with this Term Sheet to secure entry of the Stipulation and Order of Dismissal as drafted or with agreed-upon modifications; provided that nothing contained herein shall be deemed to require a Party to agree to a modification of this Term Sheet or the Stipulation and Order of Dismissal that frustrates the purpose of this Term Sheet or materially affects the economic value of the transactions contemplated hereby, the benefits to such Party under this Term Sheet, or the burdens that this Term Sheet imposes on such Party.

	Definitions	[*].
“505(b)(2) Application” has the meaning included in 21 C.F.R. § 314.3 (as amended or replaced), including all amendments and supplements to the application.
“Adamas NDA” means NDA No. 208944, including any replacements, amendments, or supplements thereto.
“Adamas Product” means [*].
“Affiliate” means (a) a Person, which directly or indirectly controls a Party; (b) a Person, which is directly or indirectly controlled by a Party; or (c) a Person, which is controlled, directly or indirectly, by the ultimate parent company of a Party.  Control, as used in clause (a), (b), or (c), is defined as owning greater than fifty percent (>50%) of the voting stock of a company or having otherwise the power to govern the financial and the operating policies or to appoint the management of an organization.
“Amantadine Patents” means any patents and patent applications that are owned or controlled by Adamas now or in the future that contain claims that cover the making, having made, importing, selling, offering for sale or use of a Generic Product or Adamas Product in or for the Territory.

Page 1 of 10

						
		“ANDA” has the meaning included in 21 C.F.R. 314.3 (as amended or replaced), including all amendments and supplements to the application.
“Authorized Generic” means a generic version of an Adamas Product that is sold or intended for sale in the Territory under the Adamas NDA without the Gocovri® trademark (or any additional or replacement trademarks).
“Commercial Marketing” shall mean the introduction or delivery for introduction into interstate or intrastate commerce of a drug product described in an ANDA or 505(b)(2) Application, outside the control of the ANDA or 505(b)(2) Application applicant, except that the term does not include transfer of the drug product for investigational use under 21 C.F.R. part 312 or transfer of the drug product to parties identified in the ANDA or 505(b)(2) Application for reasons other than sale.  For the avoidance of doubt, this definition is intended to encompass the full definition of “Commercial marketing” included in 21 C.F.R. § 314.3 (as amended or replaced).
“Commercially Reasonable Efforts” means the reasonable, diligent, and good-faith efforts as a pharmaceutical company of similar size to the corresponding Party would normally use to accomplish a similar objective under similar circumstances.  
“FDA” means the United States Food and Drug Administration.
“Final Court Decision” means a decision by a court from which no appeal has been taken or can be taken (other than by a petition to the United States Supreme Court for writ of certiorari) and it further includes a decision from a proceeding before the USPTO including an inter partes review, ex partes review, or any other proceeding from which no appeal has been taken or can be taken (other than by a petition to the United States Supreme Court for writ of certiorari).
[*].
“Generic Product” means [*].
“Launch” shall mean the actual commercial delivery of a Zydus Product to any customer.

		“Launch at Risk” means the Commercial Marketing of a Generic Product by a Third Party that is (i) prior to the earlier of (a) the License Effective Date (as defined below) or (b) a Final Court Decision that such Third Party’s Generic Product does not infringe any valid unexpired claim of the Licensed Patents; and (ii) is not licensed or otherwise authorized by Adamas prior to the date of such sales.  
“Licensed Patents” means, [*].
“Orange Book” means FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (or any successor or equivalent publication thereof).
“Orphan Drug Date” means the date that the Adamas NDA’s orphan drug exclusivity period ends, currently August 24, 2024.  
“Person” means any individual, firm, corporation, partnership, limited liability company, trust, joint venture, governmental authority, or other entity or organization. 
“Territory” means the United States, United States of America and its territories and possessions, including the Commonwealth of Puerto Rico and the District of Columbia.
“Zydus 68.5 mg Product” means Zydus’s 68.5 mg Strength product that is the subject of the Zydus ANDA.
“Zydus 137 mg Product” means Zydus’s 137 mg Strength product that is the subject of the Zydus ANDA.

		“Zydus ANDA” means ANDA No. 214897 filed by Zydus Worldwide DMCC with the FDA [*].
“Zydus ANDA Holder” means the registered holder of the Zydus ANDA.
“Zydus Product” means [*].

Page 2 of 10

						
	License Effective Date	(a)The License Effective Date for the Zydus 68.5 mg Product shall be March 4, 2030 unless [*], in which case the License Effective Date will automatically become [*].
(b)The License Effective Date for the Zydus 137 mg Product shall be the one hundred eighty-first day after the License Effective Date provided to Sandoz, Inc. for its 137 mg Strength Generic Product in the Adamas-Sandoz Binding Term Sheet dated December 30, 2019 (the “Sandoz Binding Term Sheet”), [*]; provided that if [*], the License Effective Date for the Zydus 137 mg Product shall be the later of the following dates:
i.March 4, 2030 unless [*]; or
ii.the date that [*].
(c)For the avoidance of doubt, the License Effective Date for a given strength Zydus Product shall be independent of the License Effective Date for any other strength Zydus Product and any provisions affecting or affected by the License Effective Date for one strength shall not apply to any other strength.
(d)Zydus acknowledges that Zydus’s ability to exercise its rights under the License on the License Effective Date may be restricted by [*].

	License	Subject to the terms and conditions of this Term Sheet, Adamas hereby grants to the Zydus ANDA Holder (and to the extent necessary, its Affiliates, suppliers, distributors, manufacturers, customers and assignees, as the case may be) a non-exclusive, fully paid, non-transferable license under the Licensed Patents, with no right to sublicense (the “License”), to:  
(a)make or have made a Zydus Product inside or outside the Territory [*] and solely for use, sale and offer for sale of a Zydus Product in the Territory on or after the License Effective Date; 
(b)import a Zydus Product into the Territory [*] and solely for use, sale, and offer for sale of a Zydus Product in the Territory on or after the License Effective Date;
(c)to use, sell, and offer to sell a Zydus Product in the Territory as of the License Effective Date.

	[*]	[*].

	Premarketing Rights	Adamas authorizes Zydus to [*] its Zydus Product to potential customers [*] prior to the License Effective Date but only for sales that will occur on or after the License Effective Date.
	Acceleration of License Effective Date	The License Effective Date for each Zydus Product shall be accelerated only under the circumstances specified below to the earliest of:
(a)In the event that Adamas licenses or otherwise authorizes any Third Party to sell a 68.5 mg Strength Generic Product before the above License Effective Date, then the License Effective Date  for the Zydus 68.5 mg Product shall be accelerated and amended to the date that is: 
i.[*] the date on which [*] commence selling a 68.5 mg Strength Generic Product pursuant to an application under a license, sublicense, covenant-not-to-sue or other authorization or immunity from Adamas or its Affiliates; or
ii.the date on which [*] commence selling a 68.5 mg Strength Generic Product under a license, sublicense, covenant-not-to-sue, or other authorization or immunity from Adamas or its Affiliates.
(b)In the event that Adamas licenses or otherwise authorizes any Third Party to sell a 137 mg Strength Generic Product before the above License Effective Date, then the License Effective Date for the Zydus 137mg Product shall be accelerated and amended to the date that is:
i.[*] the date upon on which [*] commence selling a 137 mg Strength Generic Product pursuant to an application under a license, sublicense, covenant-not-to-sue or other authorization or immunity from Adamas or its Affiliates or, if earlier, the date [*]; or
ii.[*], on the date that is the later of (i) the date on which [*] commence selling a 137 mg Strength Generic Product under a license, sublicense, covenant-not-to-sue, or other authorization or immunity from Adamas or its Affiliates or (ii) the date that [*].
Adamas shall provide Zydus with notice of [*] selling a Generic Product within [*].
(c)If Adamas [*], the License Effective Date will automatically accelerate to [*], except that, if [*], the License Effective Date will not be accelerated under this subsection unless (1) [*]; and (2) [*].  Adamas shall provide Zydus with notice of any [*] of execution of any agreement that would accelerate the License Effective Date. 
(d)The date on which a Final Court Decision from which no appeal has been or can be taken (other than by a petition for writ of certiorari) [*].

Page 3 of 10

						
		(e)If Adamas fails to maintain the Licensed Patents without option for reinstating them, the License Effective Date shall be accelerated to the last to expire of the Licensed Patents.  
(f)[*] after Zydus provides Adamas notice of any Market Decline Trigger Date (as described below); provided that if [*].

	Launch at Risk	(a)In the event of a Third Party Launch at Risk, then Zydus may Commercially Market the Zydus Product at-risk on the date that is the earlier of (i) [*]; or (ii) [*]; or (iii) [*].
(b)In the event of [*].

	Market Decline	If the sales of all strengths of all Adamas Products (on an aggregate basis) decline [*] over any 12-month period starting with the 12-month period ending July 31, 2025 when compared to the sales of all Adamas Products (on an aggregate basis) that occurred in the 12 month period ending December 31, 2019, the date at the end of the 12-month period in which such a decline occurred will be considered a “Market Decline Trigger Date.” The extent of the decline is to be determined by comparing the aggregate prescriptions of units of the products described in the Adamas NDA in each period [*].  This Market Decline Trigger Date cannot be the result of a bona fide interruption based on safety and/or efficacy issues raised by FDA related to an Adamas Product.  For clarity, [*].

	Licensed Products	The “Licensed Products” shall mean:
(a)The Zydus 68.5 mg Product and the Zydus 137 mg Product that are the subject of the Zydus ANDA.
(b)If Adamas [*].

	Adamas Covenant-Not-To-Sue	Subject to Zydus’s compliance with the terms of this Term Sheet, Adamas and its Affiliates covenant not to assert (i) the Licensed Patents or any other United States or foreign patent rights owned, licensed or otherwise controlled by Adamas or its Affiliates either now or in the future against the making, having made, offering for sale, sale, importation, or use of a Zydus Product or its active pharmaceutical ingredient (“API”) in or for the Territory; or (ii) any foreign patent rights owned, licensed or otherwise controlled by Adamas or its Affiliates against the making or having made a Zydus Product or its API outside of the Territory solely for the offer for sale, sale, and use of a Zydus Product in the Territory or the importation of a Zydus Product into the Territory by Zydus or on Zydus’s behalf (the “Adamas Covenant”).  Adamas shall impose the foregoing Adamas Covenant on its Affiliates and any Third Party to which Adamas or any of its Affiliates may assign, license, sublicense, or otherwise transfer any rights to or under the applicable Adamas patent or patent applications.  For the avoidance of doubt, no right, license, or covenant is granted as to the sale of Zydus Product or its API outside the Territory. 

	Zydus Covenant-Not-To-Sue	Subject to Adamas’ compliance with the terms of this Term Sheet, Zydus and its Affiliates covenant not to assert (i) [*]; or (ii) [*] (the “Zydus Covenant”).  Zydus shall impose the foregoing Zydus Covenant on its Affiliates and any Third Party to which Zydus or any of its Affiliates may assign, license, sublicense, or otherwise transfer any rights to or under the applicable patents or patent applications.  For the avoidance of doubt, no right, license, or covenant is granted as to the sale of Adamas Product or its API outside the Territory.

	Most Favored Nations	Adamas represents that [*], are equivalent to or better than such terms previously offered or currently being offered by Adamas to any Third Party with respect to any Generic Product.  If Adamas enters into an agreement with any Third Party with respect to a 68.5 mg Strength Generic Product providing such Third Party with [*]. If Adamas enters into an agreement with any Third Party with respect to a 137 mg Strength Generic Product providing such Third Party with [*]. 
	No Interference with FDA Approval	Subject to Zydus’s compliance with the terms of this Term Sheet, Adamas and its Affiliates shall not attempt to interfere with and shall not cause, authorize or encourage any Third Party to interfere with the FDA approval of a Zydus Product under the Zydus ANDA, or the ability to Commercially Market a Zydus Product as of the License Effective Date, including, but not limited to, by taking any of the following actions: (i) deleting, delisting, removing, designating as “obsolete” or cancelling the Adamas NDA or Adamas Product prior to one (1) year after the Launch of a Zydus Product in the Territory (except due to a safety issue); (ii) delisting or removing any current Licensed Patents with respect to the Adamas NDA from the FDA’s Orange Book (or any successor or equivalent publication thereof); (iii) deleting, removing, or canceling any National Drug Code(s) or any other relevant code(s) for an Adamas Product from the applicable National Drug File or from any other pricing database  prior to one (1) year after the Launch of a Zydus Product in the Territory; (iv) destroying, buying back, offering to buy back, or otherwise inducing the return of an Adamas Product (except due to a safety issue) prior to the Commercial Marketing of a Zydus Product in the Territory; (v) seeking or otherwise undertaking any action with the FDA to discontinue or withdraw an Adamas Product from the market (except due to a safety issue) prior to the one (1) year after Launch of a Zydus Product in the 

Page 4 of 10

						
		Territory; (vi) interfering with Zydus’s or its Affiliates’ efforts to obtain and maintain FDA approval of a Zydus Product and the Zydus ANDA, including, but not limited to, the filing or submission of any Citizen Petitions (except for a Citizen Petition in accordance with 21 C.F.R. § 314.127 that is filed solely for reasons of public safety or efficacy), correspondence or other written submissions with FDA or any other regulatory or governmental authority that may result in delaying or putting at risk the approval of the Zydus ANDA; or (vii) interfering with Zydus’s or its Affiliates’ ability to make, have made, import, use, offer for sale or sale of a Zydus Product as of the dates and under the terms provided by this Term Sheet.
	Early Final FDA Approval / Waiver of Regulatory or Statutory Exclusivities	Subject to the terms and conditions of this Term Sheet, Adamas will grant a waiver of any regulatory or statutory exclusivities to the extent necessary to effectuate the License and the Adamas Covenant, and solely for offering for sale, sale and use of a Zydus Product in the Territory as of the Orphan Drug Date (“Exclusivity Waiver”).  Adamas agrees to cooperate reasonably with the Zydus ANDA Holder to effectuate the selective waiver of regulatory exclusivity detailed herein, including providing notices to the FDA verifying the existence of such selective waiver and not opposing the FDA’s final approval of the Zydus ANDA for sale of a Zydus Product in the Territory as of the Orphan Drug Date.  Adamas also agrees to deliver the verification of the existence of such selective waiver in such form as FDA may require and as provided by Zydus to Adamas to both the FDA and the Zydus ANDA Holder within seven (7) business days following the Zydus ANDA Holder’s request.  As such, Adamas agrees to cooperate reasonably under 21 C.F.R. § 314.94(a)(12)(v) to provide a written statement that it waives any relevant exclusivities and consents to final approval of the Zydus ANDA as of the Orphan Drug Date.  For the avoidance of doubt, this provision solely concerns waivers required to gain final approval of the Zydus ANDA from the FDA and nothing in this provision is intended to provide Zydus with any rights to make, use, sell, offer for sale, or import a Zydus Product prior to the dates provided in the License provision, Premarketing Rights provision, and the relevant accelerators.

In addition, [*].

	Paragraph IV Certification	For the avoidance of doubt, nothing in this Term Sheet prohibits or is intended to prohibit the Zydus ANDA Holder from filing, maintaining, and/or recertifying pursuant to 21 C.F.R. § 314.94(a)(12)(v) any Paragraph IV Certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (as amended or replaced) in the Zydus ANDA to any of the Licensed Patents, and to any other patent listed in the FDA’s Orange Book now or in the future in connection with an Adamas Product. 

	No Challenge to Licensed Patents	Subject to Adamas’ material compliance with the terms and conditions of this Term Sheet, and as long as this Term Sheet is in effect, neither Zydus nor its Affiliates shall challenge the patentability, validity, enforceability or infringement of the Licensed Patents in connection with a Zydus Product, the Zydus ANDA, a 505(b)(2) Application exclusively referencing the Adamas NDA and containing amantadine as the sole active ingredient, or any other product referencing the Adamas NDA and considered a therapeutic equivalent to an Adamas Product.  In addition, neither Zydus nor its Affiliates shall assist, encourage, coordinate with, or otherwise help any Third Party in challenging the patentability, validity, enforceability, or infringement of the Licensed Patents or prosecuting, defending or settling litigation concerning its attempts to obtain approval of or sell its respective products (i) exclusively referencing the Adamas NDA and containing amantadine as the sole active ingredient or (ii) referencing the Adamas NDA and considered a therapeutic equivalent to an Adamas Product, except as required by law; provided that actions taken by Zydus to reasonably respond to a subpoena or other order of a court or other judicial or administrative body shall not be deemed to be actions that “assist, encourage, coordinate with, or otherwise help” any Third Party.  Notwithstanding the above, nothing in this provision or Term Sheet shall (i) prohibit Zydus and its Affiliates from challenging, disputing, or contesting the patentability, validity, enforceability, or infringement of one or more of the Licensed Patents in relation to a Paragraph IV Certification concerning any product other than a Zydus Product and the Zydus ANDA (but excepting any 505(b)(2) Applications that exclusively reference the Adamas NDA and contains amantadine as the only active ingredient or any other applications for products referencing the Adamas NDA and considered a therapeutic equivalent to an Adamas Product), or (ii) in the event, and to the extent, Adamas or its Affiliates, or any Third Party, initiates suit against Zydus or its Affiliates alleging that any product other than a Zydus Product or the Zydus ANDA infringes any such Licensed Patents, then Zydus or its Affiliates may seek reexamination, inter partes review, or any other post-grant review of such Licensed Patents.

	[*]
	[*].

Page 5 of 10

						
	Mutual Representations and Warranties	Each Party represents and warrants to all the other Parties that, as of the Execution Date:
(a)this Term Sheet is a legal, valid, and binding obligation of the warranting Party and its Affiliates, enforceable against such Party and its Affiliates in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium, or similar laws affecting creditors’ rights generally or by general principles of equity;
(b)the warranting Party is not subject to any judgment, order, injunction, decree, or award of any court, administrative agency, or governmental body that would or might interfere with its performance of any of its material obligations hereunder;
(c)the execution, delivery, and performance of this Term Sheet does not conflict with any agreement, instrument, or understanding, oral or written, to which such warranting party is bound, nor violate any law or regulation of any court, governmental body, or administrative or other agency having jurisdiction over it; and
(d)the warranting Party has full power and authority to enter into and perform its obligations under this Term Sheet in accordance with its terms. 

	Adamas Representation and Warranties	(a)Adamas further represents and warrants that, as of the Execution Date, subject to any security interests currently recorded with the United States Patent and Trademark Office, (i) it is the owner of all right and title to the Licensed Patents, including any patent application that may issue, and the Amantadine Patents and that Adamas has the right to settle issues relating to the Licensed Patents, and (ii) Adamas has all the legal right, power and authority to grant Zydus the licenses granted hereunder with respect to the Licensed Patents and the Amantadine Patents and the waivers and covenants granted hereunder.
(b)To the extent Adamas or any of its Affiliates assigns, licenses, sublicenses or otherwise transfers (by any means) to any Third Party any right, title or interest in or to the Licensed Patents, Amantadine Patents, or the Adamas NDA after the Execution Date, Adamas or such Affiliate will make such assignment, license, sublicense or other transfer subject to the license, waivers, covenants and other rights granted to Zydus in this Term Sheet. 

	Zydus Representations and Warranties	(a)Zydus represents and warrants to Adamas that, as of the Execution Date, (i) Zydus has the right to settle issues related to the Zydus ANDA, (ii) Zydus or its Affiliates own all right, title and interest in, to and under the Zydus ANDA, and Zydus and its Affiliates have not granted or assigned to any Third Party, directly or indirectly, any rights under or to the Zydus ANDA or a Zydus Product, (iii) Zydus and its Affiliates [*]. 
(b)Zydus and its Affiliates will not (until the occurrence of the License Effective Date or as otherwise allowed under this Term Sheet) assist, authorize or cooperate with any Third Party in the manufacturing, marketing, selling, or seeking regulatory approval for a Generic Product for the Territory; provided that actions taken by Zydus to reasonably respond to a subpoena or other order of a court or other judicial or administrative body shall not be deemed to be actions that “assist, authorize or cooperate with” any Third Party.
(c)Any breach of [*].

	Breach, Disputes, and Termination	(a)In the event of a material breach of any provision of this Term Sheet by the other party that remains uncured for forty-five (45) days after receipt of a notice by the other Party specifying in reasonable detail in writing the nature of the breach and demands its cure, either Party may, but is not required to, terminate this Term Sheet; [*].  In the event of a reasonable, good-faith dispute between the Parties as to whether a breach has occurred or a timely cure has been effectuated, the relevant period for cure shall be tolled during the time in which the Parties are actively engaged in a negotiation regarding such breach or cure.
(b)Notwithstanding anything in this Term Sheet, to the extent Zydus breaches this Term Sheet by [*].
(c)For clarity, this provision shall not be construed as a license to Zydus to make, have made, import, offer for sale, sell or use a Zydus Product in the Territory, or make or have made a Zydus Product outside the Territory for sale in the Territory, before such activities are expressly permitted herein nor as an acknowledgment or admission by Adamas that any such breach is curable, and Adamas retains all remedies available to them if Zydus or any of its Affiliates offer for sale or sell a Zydus Product in the Territory before such activities are expressly permitted herein, including the right to terminate this Term Sheet unless such breach is cured as previously set forth in this provision.

Page 6 of 10

						
	Confidentiality	The provisions of this Term Sheet and the negotiations of the Parties pertaining thereto shall be maintained in confidence by the Parties except:  
(a)it may be disclosed to a Party’s attorneys, advisors, consultants, agents, and representatives, and bona fide prospective purchasers, investors, merger partners, transferees, and assignees, who are subject to obligations of confidentiality consistent with this Term Sheet; 
(b)as is required by statute, ordinance or regulation (including pursuant to Title XI of the Medicare Prescription Drug Improvement and Modernization Act (Subtitle B – Federal Trade Commission Review)), including, without limitation, reporting requirements to the U.S. Securities and Exchange Commission or by the rules or regulations of any stock exchange to which the Parties are subject; 
(c)as is required pursuant to compulsory legal process or by discovery obligations incident to litigation; 
(d)as is necessary for the exercise of the rights granted to the Parties under this Term Sheet, including that Zydus may disclose such terms to (i) any Third Party manufacturers, service providers and suppliers on a confidential basis consistent with this Term Sheet prior to the License Effective Date to the extent necessary to enable such manufacturers, service providers and suppliers to make, have made and supply a Zydus Product (or components thereof) in accordance with the terms and conditions set forth in this Term Sheet, and (ii) FDA as may be necessary or useful in obtaining and maintaining final approval of the Zydus ANDA and Commercially Marketing a Zydus Product, when and only when as provided by this Term Sheet; 
(e)any Party may disclose that Zydus has been authorized to sell a Zydus Product as of the License Effective Date, or earlier under certain circumstances;
(f)Zydus may [*]; 
(g)Adamas may disclose [*]; or 
(h)as expressly permitted or provided in this Term Sheet, or as otherwise agreed to in writing by the Parties.
If a Party is disclosing information relating to this Term Sheet because it is required to do so to comply with statutory, regulatory or legal process requirements, including its reporting requirements under the SEC rules, or any national securities exchange on which it is listed, such Party intending to make such disclosure shall give the other Party at least [*].

	Assignment	This Term Sheet shall not be assignable in whole or in part by any of the Parties without the prior written consent of all the other Parties.  Notwithstanding the foregoing, Adamas may assign this Term Sheet to any Affiliate or to any successor or assignee of an Adamas Product business generally, and Zydus may assign this Term Sheet to any Affiliate or Third Party who acquires all or substantially all of the business to which this Term Sheet relates, i.e., the Zydus ANDA and Zydus Products, provided that in either case such Affiliate, successor, assignee or Third Party, as the case may be, agrees in writing for the benefit of the non-assigning Party to assume all of the obligations of the assigning Party hereunder.  No assignment or delegation of this Term Sheet will relieve the assigning Party from any of its obligations hereunder.

	Notice	All notices or other communications hereunder shall be deemed to have been duly given and made if in writing and if served by personal delivery upon a Party, if delivered by a reputable overnight express courier service (charges prepaid), or if sent by facsimile to the person at the address set forth below, or such other address as may be designated in writing hereafter, in the same manner, by such person as follows:
If to Adamas:
Adamas Pharma, LLC
1900 Powell Street, Suite 1000
Emeryville, CA 94608
Attn: General Counsel
generalcounsel@adamaspharma.com

Page 7 of 10

						
		And a copy to (which shall not constitute notice hereunder):
[*]
If to Zydus:
Zydus Pharmaceuticals (USA) Inc.
73 Route 31 North
Pennington, New Jersey 08534
Attn: Executive Vice President and Chief Legal Officer
And a copy to (which shall not constitute notice hereunder):
[*]
Such notices will be deemed to have been given on the date delivered in the case of delivery by personal delivery or overnight courier or on the date actually received in the case of facsimile or email delivery.

	Governing Law	This Term Sheet and any dispute arising out of or related to this Term Sheet shall be governed and interpreted in accordance with the laws of [*] without regard to conflicts of law principles.  The [*].
	Unknown Claims	In connection with this Term Sheet, each Party, on behalf of itself and its Affiliates, expressly waive and relinquish all rights and benefits afforded by Section 1542 of the California Civil Code, which provides as follows:
A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.
Further, each Party, on behalf of itself and its Affiliates, expressly waives and relinquishes all rights and benefits afforded by any law in any other jurisdiction similar to Section 1542 of the California Civil Code.

	Counterparts	This Term Sheet may be executed in any number of signature page counterparts, any one of which need not contain the signature of more than one Party, but all such counterparts taken together shall constitute one and the same Term Sheet.
	Entire Agreement	This Term Sheet (which includes the attached unfiled Stipulation and Order of Dismissal) constitutes the entire agreement between the Parties with respect to the subject matter hereof, and no oral or written statement that is not expressly set forth in this Term Sheet may be used to interpret or vary the meaning of the terms and conditions hereof.  This Term Sheet supersedes any prior or contemporaneous agreements and understandings, whether written or oral, between the Parties with respect to the subject matter hereof.
	Severability	When possible, each provision of this Term Sheet will be interpreted in such manner as to be effective and valid under applicable law.  If, however, any provision of this Term Sheet is held to be invalid, illegal, or unenforceable for any reason, the Parties shall negotiate in good faith for a substitute provision to continue the intent and purpose of such invalid provisions, and the validity, legality, and enforceability of the remaining provisions shall not be in any way impaired thereby.
	Mutual Release	Upon the terms and subject to the obligations and conditions of this Term Sheet each Party on behalf of itself and its Affiliates hereby fully, finally and irrevocably releases, acquits and forever discharges the other Party and its Affiliates from any and all losses that are in any way related to the actions or events occurring from any time in the past prior to the Execution Date arising out of, derived from, predicated upon or relating to (i) infringement of the Adamas Patents by the Zydus ANDA or a Zydus Product; (ii) the actions underlying Zydus’s Paragraph IV Certifications; (iii) the Zydus ANDA and/or a Zydus Products; (iv) and/or Adamas’ enforcement of its rights under said patents, including without limitation actions relating to obtaining patents or other intellectual property, submitting such patents to the FDA for listing in the Orange Book, and commencing, conducting, and settling issues relating to the Licensed Patents.  Notwithstanding the foregoing, nothing in this Mutual Release shall prevent or impair the right of either Party to bring a proceeding in the District Court for breach of this Term Sheet or other cause(s) of action or remedy permitted under this Term Sheet.
	Reservation of Rights	All rights not expressly granted to Zydus hereunder are expressly reserved to Adamas, and Adamas has no obligation to make available any intellectual property rights or to take any other actions other than as expressly set forth herein.

Page 8 of 10

						
	Disclaimer	Except as expressly provided in this Term Sheet, neither party makes any representations or warranties, express or implied, either in fact or by operation of applicable law, and each party hereby expressly disclaims any such other representation or warranties.
	No Waiver	The failure of any Party to enforce at any time for any period the provisions of or any rights deriving from this Term Sheet shall not be construed to be a waiver of such provisions or rights or the right of such Party thereafter to enforce such provisions.

[remainder of page intentionally left blank]
Page 9 of 10

IN WITNESS WHEREOF, this Term Sheet has been executed by the Parties as of January ____, 2021 (the “Execution Date”).

																		
	ADAMAS PHARMA, LLC		ZYDUS WORLDWIDE DMCC	
						
	By:	/s/ Neil F. McFarlane		By:	/s/ Ketankumar Bhut	
	Name:	Neil F. McFarlane		Name:	Ketankumar Bhut	
	Title:	CEO		Title:	Director	
						
				ZYDUS PHARMACEUTICALS (USA) INC.	
						
				By:	/s/ Brij Khera	
				Name:	Brij Khera	
				Title:	EVP & Chief Legal Officer	

Page 10 of 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]